Optimizing Micafungin Dosing in Children
Wei Zhao,William W Hope,Paolo Manzoni,Evelyne Jacqz-Aigrain
DOI: https://doi.org/10.1097/inf.0b013e3182624bac
2012-01-01
The Pediatric Infectious Disease Journal
Abstract:To the Editors: We read with interest the article by Undre et al1 reporting the pharmacokinetic subanalysis of micafungin and its metabolites (M1, M2 and M5) in children, based on a nested substudy from a phase 3 trial, which demonstrated that micafungin was noninferior to liposomal amphotericin B for the treatment of invasive candidiasis and candidemia, and was better tolerated in children.2 The authors concluded that, although a trend toward lower exposures was shown in children younger than 5 years (n = 7), recommendations for increased dosing adjusted for this age group cannot be made. As pediatric clinical pharmacologists, we would be interested to know how the authors reached this conclusion. Among echinocandins, micafungin is the best-studied antifungal agent in pediatric patients and is indicated for use in children, including neonates, in a daily dosage of 2–4 mg/kg for treatment of invasive candidiasis. According to regulatory guidelines,3 the pharmacokinetic–pharmacodynamic relationship of micafungin can be assumed to be similar across all pediatric age groups, and similar micafungin exposures should be achieved to reach similar efficacy in adults and children. The pharmacokinetic study in adults has demonstrated that 100 mg micafungin resulted in an average area under the concentration curve time from zero to 24 hours (AUC0–24 ) of 101.6 μg·h/mL in steady-state conditions,4 This is much higher than the AUC values reported in the present pediatric study, in particular for young children (81.7 μg·h/mL for children ≥ 5 years [n = 5]; 53.82 μg·h/mL for children < 5 years [n = 7]).1 Furthermore, the pathogenesis and subsequent risks associated with invasive Candida infections are distinct in preterm neonates compared with older children and adults. Preterm neonates have the potential to develop central nervous system (CNS) infection, because the brain–blood barrier is immature. To avoid central nervous system infection, a higher AUC target of 166.5μg·h/mL should be used,5–7 with appropriate higher dosing regimen in preterm neonates. A population pharmacokinetic analysis has shown that a dosing regimen of 10 mg/kg/d results in 82.6% of patients with AUCs that are associated with near-maximal decline in fungal burden within the central nervous system.5 This dosing regimen is much higher than the current dosing recommendation for neonates. The authors argued that this lower micafugin exposure was not associated with decreased efficacy and that none of the children required a dose increase due to the lack of efficacy. However, it should be highlighted that the number of children included was limited in all the reported studies, and there were no neonates. There remains an urgent need to optimize micafungin regimens based on pharmacokinetic/pharmacodynamic data and to evaluate the resultant clinical outcomes. Wei Zhao, PharmD, PhD Université Paris Diderot, Sorbonne Paris Cité AP-HP, Department of Pediatric Pharmacology and Pharmacogenetics Hôpital Robert Debré INSERM Clinical Investigation Center CIC9202 Paris, France William W. Hope, MD, PhD University of Manchester, Manchester Academic Health Science Centre NIHR Translational Research Facility in Respiratory Medicine University Hospital of South Manchester NHS Foundation Trust Manchester, United Kingdom Paolo Manzoni, MD Department of Neonatology and NICU S. Anna HospitalTorino, Italy Evelyne Jacqz-Aigrain, MD, PhDUniversité Paris Diderot, Sorbonne Paris CitéAP-HP, Department of Pediatric Pharmacology and PharmacogeneticsHôpital Robert DebréINSERM Clinical Investigation Center CIC9202 Paris, France Evelyne Jacqz-Aigrain, MD, PhD Université Paris Diderot, Sorbonne Paris Cité AP-HP, Department of Pediatric Pharmacology and Pharmacogenetics Hôpital Robert Debré INSERM Clinical Investigation Center CIC9202 Paris, France